BRAF and melanoma: In fact, the discovery of BRAF mutations occurring in about 50% of melanoma patients encouraged the use of a BRAF inhibitor in melanoma patients carrying the BRAFV600E mutation: the results obtained in various clinical studies (phase I, II, and III trials) have supported a clinical activity of vemurafenib, a BRAF inhibitor.